2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma
CABRERA R, FITIAN A, ARARAT M, XU Y, BRUSKO T, WASSERFALL C, ATKINSON M, LIU C, NELSON D. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncology Letters 2012, 4: 840-846. PMID: 23205111, PMCID: PMC3506698, DOI: 10.3892/ol.2012.826.Peer-Reviewed Original ResearchSerum levelsEarly hepatocellular carcinomaHepatocellular carcinomaHCC presenceSoluble CD25Pg/Levels of sCD25Healthy control subjectsNovel predictive markerAdvanced cirrhosisPresent study studyAdvanced fibrosisTumor burdenTumor stageControl subjectsHCC patientsPredictive markerImmune factorsGlobal unmet needLarge cohortSCD25PatientsSmall seriesUnmet needSignificant positive correlation
2010
Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma
Cabrera R, Ararat M, Eksioglu E, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson D. Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma. Scandinavian Journal Of Immunology 2010, 72: 293-301. PMID: 20883314, PMCID: PMC2951624, DOI: 10.1111/j.1365-3083.2010.02427.x.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHCC serumSerum-free mediumSoluble CD25Pg/Effector T cell responsesEffector T cell functionSerum-mediated suppressionRegulatory T cellsT cell responsesSera of patientsT cell functionHealthy control cellsNovel therapeutic targetDose-dependent fashionCD25 cell surface expressionTeff responsesTreg suppressionInfluence of serumCirrhosis patientsTeff proliferationTumor burdenCD25 expressionCell surface expressionPoor survival
2009
Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson M, Liu C, Nelson D. Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25). Digestive Diseases And Sciences 2009, 55: 484-495. PMID: 19714465, PMCID: PMC3161029, DOI: 10.1007/s10620-009-0955-5.Peer-Reviewed Original ResearchConceptsT cell responsesHCC patientsHepatocellular carcinomaCell responsesTumor burdenImpaired T cell responsesLower IFN-γ productionEffector T cell responsesIL-2 receptor alpha chainATP production assaysLevels of sCD25Tolerogenic tumor environmentIFN-γ ELISPOTEffector T cellsT cell immunityT cell reactivityIFN-γ productionIL-2 supplementationT cell defectsDose-dependent mannerReceptor alpha chainIL-2 signalingSerum sCD25Soluble CD25Worse survival